Generic drugs

Lilly scores series of small victories

November 17, 2010
J.K. Wall
The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
More

Court upholds Lilly patent on cancer drug Alimta

November 16, 2010
 IBJ Staff and Associated Press
A U.S. District Court judge on Monday upheld Eli Lilly and Co.’s patent on the cancer drug Alimta, protecting the compound until July 2016. It was a welcome win after a difficult few months for Indianapolis-based Lilly, which is facing a wave of patent expirations in coming years.
More

Appeals court rejects Lilly over Gemzar patent

November 1, 2010
 IBJ Staff and Bloomberg News
Without an appeal, generic drugs are now poised to wipe away most of Lilly's $750 million in annual U.S. revenue from Gemzar.
More

Consultants: Pharma industry facing huge changes

October 6, 2010
J.K. Wall
Heitzman_WatchVideoTo date, most analysts say health reform turned out pretty well for the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen over the past three decades.
More

Lilly sues drug distributor over generic Zyprexa sales

September 29, 2010
Bloomberg News
Celesio's Lloyds Pharmacy and Aah Pharmaceuticals businesses sold about 800,000 tablets of generic Zyprexa before agreeing in 2008 to halt sales, Lilly said in a complaint filed in the High Court in London.
More

Appeals court ruling upholds Lilly's Evista patents

September 1, 2010
Bloomberg News
Eli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic version of the Evista osteoporosis treatment before March 2014.
More

Lilly wins ban of generic Strattera pending appeal

August 31, 2010
Bloomberg News
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until the court rules on a judge's decision invalidating a patent on the medicine.
More

Lilly wins further delay in sales of Strattera copies

August 26, 2010
Bloomberg News
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would translate into an average $1.22 million in sales.
More

Lilly wins temporary ban on sales of Strattera copies

August 19, 2010
Bloomberg News
The invalidation of Lilly's Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug, which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
More

Eli Lilly loses patent lawsuit for Strattera

August 13, 2010
 IBJ Staff and Associated Press
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
More

Lilly loses appeal over patent for cancer drug Gemzar

July 28, 2010
 IBJ Staff and Bloomberg News
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013. Gemzar generated $1.36 billion in global sales in 2009.
More

Lilly sues to block copy of Evista osteoporosis drug

May 5, 2010
Bloomberg News
Watson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.'s osteoporosis medicine. Indianapolis-based Lilly is seeking a court order that would block approval until three of its patents expire in 2017.
More

Lilly wins court ban on generic copy of Gemzar

April 1, 2010
Bloomberg News, Associated Press
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version of the cancer drug Gemzar until November.
More

Lilly sues Hospira over generic version of Gemzar

March 24, 2010
Bloomberg News
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the cancer drug Gemzar before a patent on the medicine expires in 2013.
More
Page  << 1 2 pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. $800M is a lot. There's over 800,000 people in the county/city though. I'm betting the cost of services(police, fire, roads, economic incentives to bring in new business, etc.) in Hamilton County is much more than $1000 per person. In 2012, the city of Carmel's audit report shows receipts of $268,742,988 (about 1/3 of Indianapolis's receipts) for a population of 83,573 (almost 1/10 the size of Indianapolis)...hmm, I wonder why Carmel is such a safer place to live...

  2. Would you let a mechanic diagnose your car over the internet without seeing it or taking it for a test drive? The patient needs face to face interaction with a physician to be properly diagnosed. It would seem to me that the internet diagnosis is about as silly as going to ones mirror and saying, "I wonder what I have"? And then you diagnose yourself. That's free and probably wrong too.

  3. Maybe if we treated the parents of juvie offenders who have 5 babies from 4 different daddies like stray cats and dogs who go around creating a bigger animal control problem, we wouldn't have so much of a "parenting" problem flooding both the social services and (later) correctional systems. The breakdown of morals and parental responsibilities from horndogs who can't keep it in their pants and keep their families together has caused this. If a pit bull attacks someone, it's destroyed. Everyone encourages that pets are spayed and neutered to control the pet population and prevent further issues. Maybe it's time to control the welfare population...

  4. Blocking two blocks of a street along Broadripple Ave. is not going to stop "pedestrians" from walking around. The article stated that seven people were injured as a result of a skirmish between two gun-toting "pedestrians"...not drive-bys. Most of the crimes that are committed in BR area are done by "pedestrians" that are walking in the area...not driving by. This may alleviate traffic going through the area and may steer some folks away from coming to the area because of the extra inconvenience but it will not stop a pedestrian, on foot from toting a gun while walking in that area....period.

  5. Please run for mayor Joe. We need someone to come in and clean house. They past two mayors have run administrations rampant with corruption. We need to clean house before corruption is accepted as normal like Chicago.

ADVERTISEMENT